GRI Bio
GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure.
Last updated on
About GRI Bio
Founded
2009Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$14MCategory
Sector
Commercial Physical and Biological ResearchIndustry Group
Research, Development, and Testing ServicesIndustry
BiotechnologyLocation
City
La JollaState
CaliforniaCountry
United StatesGRI Bio
Find your buyer within GRI Bio
Tech Stack (39)
